Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | Updates in immunotherapy for multiple myeloma: BiTEs & novel targets

Adam Sperling • 13 Jun 2022
EHA 2022
Multiple Myeloma Antibodies CAR-T

Adam Sperling, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, shares his thoughts on the most exciting developments in the field of immunotherapy for multiple myeloma, including BCMA-targeting CAR-T therapies, bispecific T-cell engagers (BiTEs), and novel target antigens. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Adam Sperling

The impact of clonal hematopoiesis on treatment strategies for Waldenström’s macroglobulinemia 1:04
The impact of clonal hematopoiesis on treatment strategies for Waldenström’s macroglobulinemia
Adam Sperling • 18 Oct 2024
Detecting clonal hematopoiesis in patients with Waldenström’s macroglobulinemia 1:08
Detecting clonal hematopoiesis in patients with Waldenström’s macroglobulinemia
Adam Sperling • 18 Oct 2024
Clonal hematopoiesis increases the risk of progression in patients with asymptomatic WM 1:28
Clonal hematopoiesis increases the risk of progression in patients with asymptomatic WM
Adam Sperling • 18 Oct 2024
Mechanisms behind the loss of BCMA in multiple myeloma & options for patients 1:48
Mechanisms behind the loss of BCMA in multiple myeloma & options for patients
Adam Sperling • 27 Sep 2023

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals